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isoforms that have been associated with cellular resistance to
ionizing radiation.3
We want to bring attention to some significant unsolved
issues. Frequency of this new mutation in AML population is
unknown at present, since all large studies where NPM1
mutations were determined only involved exon 12 amplification
from genomic DNA or use of specific probes for known
mutations precluding exon 11 region4–7 (see references cited
in Mrozek et al.1), which let in all cases this new truncation
mutation go unnoticed. Even recommended immunohistochem-
ical determinations2 may have failed detecting this alteration,
due to its mixed staining pattern. New analyses of the thousands
of samples available in large leukaemia study groups would
allow to obtain the frequency for this new type of NPM1
mutation, thus opening the possibility of redefining new
subclasses of AML-NK based in these molecular findings. At
this point, it is interesting to add that in their recent review2
Falini et al. mentioned an abstract where the presence of
an exon 11 mutation in an AML patient is described (Albiero et al.
Haematologica 2006; 91: 237, abstract). The reported mutation at
exon 11 is the same kind of eight nucleotide insertion as the one
we have found and reported here, but the inserted nucleotides are
different in sequence, although both alterations produce a similar
truncated protein. These data reinforce the possibility that a new
hot spot for insertional mutation in NPM1 might have been
located and strengthen the need for establishing the frequency of
this type of mutation in AML patients as well as the biological
consequences of this new finding.
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Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant
fraction of myeloid sarcomas
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published online 19 April 2007
Detection of genetic lesions is critical for classification,
prognostic stratification and monitoring of minimal residual
disease of acute myeloid leukaemia (AML). Information on
genetic lesions associated with myeloid sarcoma (MS), a tumor
mass consisting of myeloblasts or immature myeloid cells at an
extramedullary site,1 is still limited.2 This is mainly due to the
fact that fresh cells are usually not available for cytogenetic and/
or molecular studies. In fact, the diagnosis of MS is frequently
unexpected and/or the size of the sample is small, such as a skin
punch biopsy. Since MS is usually treated in the same way as
AML, the frequent lack of available cytogenetics in MS
represents a significant disadvantage, and the availability of
techniques applicable to paraffin samples to detect specific
genetic lesions would be of great help both for diagnostic and
prognostic purposes.
Nucleophosmin (NPM) 1 mutations with consequent aberrant
cytoplasmic expression of NPM3,4 represent the most common
genetic abnormality in AML, but no information is available on
the role of NPM in MS. Since immunohistochemical detection of
cytoplasmic NPM in AML predicts NPM1 mutations,5 we used
anti-NPM antibodies4 to detect cytoplasmic/mutated NPM in
181 paraffin-embedded MS samples (characteristics of these
cases are provided in the Supplementary Information). Immu-
nohistochemical results were confirmed in a subset of cases by a
PCR assay that we developed for application on formalin-fixed
samples. We found 26 NPMcþ MS, whose biological and
clinical features are reported here.
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The 181 MS samples were first immunostained with the
monoclonal antibody (mAb) 376 (recognizing both wild-type
and mutated NPM proteins) (Supplementary Information).
Immunostaining results were evaluable in 173/181 MS cases;
in eight cases, they were difficult to interpret because of the
small size of tissue samples, shrinkage artefacts and/or antigenic
denaturation of the NPM protein. In 147/173 cases (85.0%),
NPM showed a nucleus-restricted expression that was identical
to nucleolin (C23) (Figure 1). This staining pattern is known to
predict absence of NPM1 mutations, as reported previously in
AML.5 In 26/173 cases (15.0%), aberrant cytoplasmic NPM
expression was detected (Figure 2; Table 1), a staining pattern
that is known to predict NPM1 mutations.5 The leukaemic cells
from these cases also showed nuclear NPM positivity (Figure 2),
due to the residual NPM wild-type protein in the nucleus.4 All
NPMcþ MS cases showed the expected nucleolin/C23 nucleus-
restricted positivity (Figure 2).
NPM1 mutations are consistently heterozygous;3,4 therefore,
leukaemic cells contain both wild-type and mutated NPM
proteins. Anti-NPM mAb 376 cannot discriminate between
these two types of proteins.4 To confirm that in MS samples,
cytoplasmic NPM dislocation is the consequence of NPM1
mutations, we stained paraffin sections by the alkaline
phosphatase anti-alkaline phosphatase (APAAP) technique using
polyclonal antibodies (Sil-A and Sil-C) that specifically recog-
nize NPM mutant proteins (Supplementary Information).
Immunostaining was performed on 18/26 NPMcþ MS samples
for which a sufficient amount of paraffin-embedded material
was available for analysis. Antigenicity of NPM mutant proteins
was preserved in 14/18 immunostained cases. Paraffin sections
from 15 NPM cytoplasmic-negative (NPMc) MS specimens
served as negative controls. In the 14 NPMcþ MS samples,
where antigenicity was preserved, expression of NPM mutant
protein was consistently cytoplasmic-restricted (Figure 3). This is
in keeping with previous findings in NPMcþ AML,4 and with
the observation that, in transfected cells, NPM mutant constructs
localize exclusively in the cytoplasm.4 With one exception,
none of the NPMc MS reacted with Sil-A and Sil-C. The
discrepant case was included in the subset of cases, which were
subjected to PCR sequence analysis (see below).
To confirm further that subcellular NPM immunostaining
pattern in MS samples predicts NPM1 gene mutations, a PCR
assay was designed that is suitable for application on RNA
extracted from formalin-fixed paraffin-embedded samples (FFPE)
(technical details are given in the Supplementary Information).
We selected 16 MS samples for the analysis (7 NPMcþ , 9
NPMc). An evaluable PCR product was obtained in 12/16
cases investigated (5 NPMcþ , 7 NPMc) (Table 2). In 11/12 of
these cases (5 NPMcþ , 6 NPMc) the aberrant cytoplasmic
localization of NPM correlated with the presence or absence of
NPM1 mutations (Table 2); in one case (case 6) the result was
Figure 1 NPMc myeloid sarcomas. (Top panels) MS of the skin
showing nucleus-restricted NPM (mAb 376). E indicates epidermis.
APAAP technique; hematoxylin conterstaining. (Middle panels) MS of
the intestine. Leukaemic cells are myeloperoxidase-positive (MPO,
left) and show nucleus-restricted positivity for NPM (mAb 376) (right).
Asterisks indicate the lumen of residual glands. APAAP technique;
hematoxylin conterstaining. (Bottom panels) MS of the bone.
Leukaemic cells with monoblastic appearance (left, hematoxylin–
eosin); mitoses (arrow) are numerous. Leukaemic cells show nucleus-
restricted expression of NPM (mAb 376) (right); the arrow indicates the
expected NPM cytoplasmic positivity of a mitotic figure. APAAP
technique; hematoxylin counterstaining.
Figure 2 NPMcþ myeloid sarcomas. (Top panels) MS of the skin.
Leukaemic cells show cytoplasmic (and nuclear) positivity for NPM
(mAb 376) (left); while cells of epidermis (E) exhibit nucleus-restricted
expression of NPM (mAb 376) (left). Leukaemic cells show the
expected nucleus-restricted positivity for C23/nucleolin (right); the
same staining pattern is observed in the cells of epidermis (E) (right).
APAAP technique; hematoxylin counterstaining. (Middle and bottom
panels) MS of the lymph node. Leukaemic cells show a monoblastic
appearance (middle left, hematoxylin–eosin) and are CD34negative
(middle right); positive vessels serve as positive internal control for
CD34; F indicates a residual lymphoid follicle. Leukaemic cells are
CD68positive (mAb PG-M1) while B cells of a residual follicle (F) are
negative (with the exception of scattered macrophages) (bottom left).
Leukaemic cells show cytoplasmic (and nuclear) NPM positivity
(bottom right); cells of the residual follicle (F) show the expected
nucleus-restricted NPM expression (bottom right). APAAP technique;
hematoxylin conterstaining.
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discrepant. This case scored nuclear (NPMc) with clone 376
but cytoplasmic with Sil-A and Sil-C antibodies (Table 2). The
PCR assay revealed a mutated sequence, indicating that the
immunostaining for mutated NPM predicted the mutations
correctly (Table 2). Possibly, in this particular case, the epitope
recognized by mAb 376 on wild-type NPM was better preserved
than that recognized by sil-A and sil-C in mutated NPM, thus
explaining the nucleus-restricted positivity that in NPMcþ AML
is mostly accounted by the residual wild-type NPM.4 Compari-
son of the mutated sequences found in this study to published
data, showed that five cases harbored the NPM1 type A allele3
and one case contained the Km allele.6
The clinicopathological and cytogenetic features of the 26
NPMcþ MS are shown in Table 1. The male/female ratio was
1.00, similar to the NPMc cases (1.03). Mean age of patients
was 62.2 years (range 11–86) not significantly different from
NPMc cases (mean age 55.6 years, range 11–86). The most
frequently involved sites were skin and lymph nodes; other
extramedullary sites were involved less frequently (Table 1). In
24 patients, the tumor was localized; one patient (Table 1, case
25) showed multiple skin involvement, and one patient (Table 1,
case 13) showed involvement of multiple sites (liver, lymph
node and soft tissue). Fourteen patients (Table 1, cases 1–14)
presented with de novo NPMcþ MS and in 5/14 (Table 1, cases
10–14) bone marrow involvement was documented within 6
months after the diagnosis of MS. In six patients (Table 1, cases
15–20), MS and AML were concurrent. In five patients, MS was
subsequent to diagnosis of AML (Table 1, cases 21–25) and in
one of them (Table 1, case 25), which was reported previously,7
skin involvement occurred 20 years after initial AML diagnosis.
No data on bone marrow status were available in case 26. There
was no history of a chronic myeloproliferative disorder or a
myelodisplastic syndrome in any case.
Classification according to FAB was possible in 21/26 cases,
and 17/21 (80.9%) were of myelo-monocytic or monocytic
origin (M4 n¼ 4; M5 n¼ 12; M4 vs M5 n¼ 1) (Table 1). M4
Table 1 Clinicopathological features of 26 NPMc+ myeloid sarcomas
No. ID no. Age/sex Site FAB BM involvement CD34
(%)
Therapy Cytog./FISH Outcome Survival
(Months)
1 H4796-04 47/F Cervix M4 No 0 NA NA Dead 4
2 H4769-99 79/M Skin M4/M5 No 0 NA NA Dead 2
3 H1636-99 69/M Liver M5 No 0 NA NA Dead 41
4 H4794-91 49/M Paraspinal M1 No 0 Ara-c NA Dead 26
5 H9240-96 79/F Skin M5 No 0 Chemo. NA Dead 8
6 H1475-95 76/F Stomach M5 No 0 Chemo. NA Dead 4
7 H4495-05 53/M Gluteus M4 No 30 NA NA Dead 1
8 H8266-97 86/F Vulva M4 No 0 Chemo. NA Dead 8
9 E2110/02 48/M Testicle M5a No 0 NA NA Dead 12
10 H12213-99 79/M Soft tissue M2 Yes (subsequent) 0 Radiation NA Dead 1
11 H4386-94 53/M Stomach M5 Yes (subsequent) 0 NA NA Dead 11
12 H7901-04 70/F Skin NA Yes (subsequent) 0 Chemo. NA Dead 7
13 S98-98 59/M Liver, LN, Soft tissue M5 Yes (subsequent) 0 Ara-c, Dauno. NA Dead 11
14 S231-95 86/M Lung NA Yes (subsequent) 0 Chemo. NA Dead 3
15 E384/02 55/F LN M5 Yes (concurrent) 0 Trisomy 8a Dead NA
16 E4962/02 80/F Skin M5b Yes (concurrent) 0 HU + PDS 46XX Dead 5
17 E1446/04 46/F Gums M5 Yes (concurrent) 0 Chemo. NA Dead 8
18 O1 63/F LN M5 Yes (concurrent) 0 Chemo. 46XX Alive 96
19 Q1 11/M Eye NA Yes (concurrent) 54 Chemo. 46XX Alive 72
20 PG-1 75/M LN M5 Yes (concurrent) 0 Chemo. 46XY
21 E6420/02 78/M Skin NA Yes (preceding) 0 Ara-c + TG NA Dead 4
22 E1 47/M Common bile duct NA Yes (preceding) NA NA NA Dead 19
23 T1 76/F Gums M1 Yes (preceding) NA Chemo. NA Dead 10
24 PG-2 53/F Skin M5b Yes (preceding) 0 Chemo./Allo. 46xx Dead 24
25 PG-3 24/F Skin M4 Yes (preceding)b 0 Chemo. 46xx Alive 10
26 H11038-89 77/F Cervix M2 NA 0 NA n.a. Dead 3
Abbreviations: Allo, allogeneic peripheral stem cell transplantation; Ara-c, cytosine-arabinoside; Chemo, chemotherapy; Dauno, daunorubicine;
HU, hydroxyurea; LN, lymph node; NA, not available; PDS, prednisone; TG, thioguanine; VBS, vinblastine.
aDetected by FISH on lymph node cells.
bSkin involvement 20 years after the initial diagnosis of AML.7 None of the cases was preceded by a chronic myeloproliferative disorder or
myelodisplastic syndrome.
Figure 3 Labelling of mutated NPM in myeloid sarcoma. (Left) MS of soft tissue. Leukaemic cells are large and vacuolated (hematoxylin–
eosin). (Middle) mAb 376 (recognizing wild-type and mutated NPM) labels both the nucleus and cytoplasm of leukaemic cells. (Right) Expression
of the mutated NPM protein (NPMm) recognized by the Sil-C antibody is cytoplasmic-restricted. The arrows in all figures indicate leukaemic cells
with a ‘signet ring’ appearance. APAAP technique; hematoxylin counterstaining.
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cases were characterized by expression of myeloperoxidase and
macrophage-restricted CD68 (PG-M1); M5 cases were positive
only for macrophage-restricted CD68. The other 4/21 cases
showed M1 (n¼ 2) or M2 (n¼ 2) morphology. These cases
showed positivity for myeloperoxidase (range 20–100% of blast
cells), in the absence of macrophage-restricted CD68. CD34
expression could be assessed in 24 cases; 22/24 (91.7%) were
CD34 negative. Cytogenetics and/or FISH were available only
in seven patients; six exhibited a normal karyotype and one
showed trisomy 8. Only 3/26 patients are alive (follow-up of 10,
72 and 96 months).
Clinical and pathological data were available in 126 out of
the 147 NPMc MS samples (Supplementary Table). The
NPMc and NPMcþ MS cases clearly differed in respect to a
previous chronic myeloproliferative disorder or a myelodys-
plastic syndrome (39.6% in NPMc vs 0% in NPMcþ , 0.001)
and the frequency of cases showing CD34 positivity (12% in
NPMc vs 47.85% in NPMcþ , Po0.001). Moreover, NPMc
MS cases showed a higher frequency of cytogenetic abnormal-
ities, as only 4/21 patients (19%) for whom cytogenetics was
available had normal karyotype, vs 6/7 NPMcþ cases (85.7%)
(Po0.001). The 17 NPMc MS cases with an abnormal
karyotype (81%) showed the following cytogenetic abnormal-
ities: t(8;21)(q22;q22) (n¼ 3); t(9;22)(q34;q11.2) (n¼ 3 chronic
myeloid leukaemia in transformation); t(15;17)(q22;q21) (n¼ 1);
47,XX,þ 5, t(8;21)(q22;q22) (n¼ 1); 47XY,?þ 2, t(6;11),12,?þ
21(n¼ 1); 47,XX,þ 8 (n¼ 1); 47,XX,þ 8, t(9;22)(q34;q11.2)14/
t(9;22)(q34;q11.2)4 (n¼ 1 chronic myeloid leukaemia in
transformation); 47,XX, t(2;5)(q35;q22),þ 8 (n¼ 1); 46XX/
46,XX, t(11;11)(p15;q22) (information on the number of mitosis
analyzed is not available) (n¼ 1); and complex karyotype
(n¼ 4). According to the method of Kaplan–Meier, the prob-
ability of the overall survival of the NPMc MS cases was 0.089
at 2 years, not statistically different from the overall survival of
the NPMcþ patients (median survival time 8 and 9 months
respectively).
In this study, we used immunohistochemistry to search for
aberrant cytoplasmic NPM expression in 181 MS samples and
detected it in 15% of them. Immunohistochemistry can serve as
a surrogate for molecular studies for detecting NPM1 mutations
in MS in most instances. In the few remaining cases, where
interpretation of immunohistochemistry is difficult because of
shrinkage artefacts and/or poor antigen preservation, the
mutational status of NPM1 gene can be assessed by PCR from
the same biopsies. Thus, the combination of the two methods
allows to overcome the lack of fresh material for diagnosis
of MS.
Notably, our results identify NPM1 mutations as the most
frequent molecular lesion so far reported in MS, defining the
molecular status in 15% of cases. NPMcþ MS showed the same
distinctive features as de novo NPMcþ AML,3 that is, frequent
association with M4 and M5 FAB categories, lack of CD34
expression and association with normal karyotype. The presence
of trisomy 8 in one case concurs with previous observations that
about 14% of NPMcþ AML carry minor chromosomal
abnormalities, which are probably secondary events.3,4 As in
NPMc AML,3 all MS cases carrying major genetic abnormal-
ities, including t(8;21), MLL rearrangement, t(15;17) and
complex karyotypes showed nucleus-restricted NPM expres-
sion, indicating the absence of NPM1 mutations. Nucleus-
restricted NPM expression was also observed in all 24 MS cases,
arising in a setting of myelodysplasia or a chronic myeloproli-
ferative disorder, consistent with the finding that NPMcþ AML
is usually a de novo leukaemia.3 Our findings that NPMcþ MS
progressing to AML as well as NPMcþ AML relapsing as MS
maintained, in these different stages of the disease, the aberrant
cytoplasmic expression of NPM is in keeping with the previous
reported stability of NPM1 mutations.8
In AML, NPM1 mutations in the absence of FLT3-ITD identify
a subgroup of patients with favorable prognosis.4,6 In contrast,
only 3/26 of NPMcþ MS patients are still alive. Several reasons
may underlie this discrepancy. Because of lack of fresh material,
information on FLT3 status is lacking in our patients. Advanced
age is a known poor prognostic factor in AML; 15/26 patients
with NPMcþ MS were older than 60 years. Treatment of
patients in this series was very heterogeneous. Moreover, due to
advanced age and delay in diagnosis, many patients underwent
only radiotherapy or chemotherapy with one or two cytotoxic
drugs.
Our results have important clinico-diagnostic implications.
Morphologically, MS may be misdiagnosed as lymphoblastic or
diffuse large-cell lymphoma or non-haematopoietic tumor.
Immunophenotyping is mandatory for diagnosis1 and the
diagnostic panel usually include antibodies against myeloper-
oxidase, CD68, CD117, CD79a, CD3, glycophorin-A, CD61
and CD34. Our results clearly indicate that anti-NPM antibodies
Table 2 NPM1 gene sequencing results in comparison with immunohistochemical stainingsa
Case ID no. Anti-NPMb Sil-A or Sil-Cc NPM1 gene sequence
1 H4796/04 NPMc+ Positive Type Ad
2 H1475/95 NPMc+ Positive Type A
3 H12213/99 NPMc+ Positive Type A
4 H7901/04 NPMc+ Positive Type Kme
5 H11038/89 NPMc+ Positive Type A
6 H16916/03 NPMc Positive Type A
7 H15647/00 NPMc Negative Wild-type
8 H2250/03 NPMc Negative Wild-type
9 H15319/96 NPMc Negative Wild-type
10 H8848/98 NPMc Negative Wild-type
11 H17905/98 NPMc Negative Wild-type
12 H20049/90 NPMc Negative Wild-type
aCarried out in FFPE sections.
bMonoclonal antibody 376 reacts with both the mutant and wild-type NPM.
cPolyclonal antibodies that specifically recognize NPM mutants.
dSee Falini et al.3
eSee Schnittger et al.6
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should be added to this panel as they predict NPM1 mutations.
Our data also provide a rationale for a genetic-oriented
classification of MS in the upcoming version of WHO
classification.1 Future efforts should integrate data on NPM1
and FLT3-ITD status, to determine in prospective studies
whether MS carrying mutated NPM in the absence of FLT3-
ITD also constitutes a more favorable prognostic category, as
has been reported for de novo NPMcþ AML.4,6
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Thrombosis can occur at any phase of essential thrombocythemia with JAK2V617F
mutation: a single institutional study in Japan
Leukemia (2007) 21, 1570–1571; doi:10.1038/sj.leu.2404666;
published online 29 March 2007
The JAK2V617F mutation is an activating kinase that is constitu-
tively expressed in the vast majority of patients with polycythemia
vera and approximately half of those with essential thrombo-
cythemia (ET).1 The significance of the association between
JAK2V617F mutation in ET and thrombosis is still controversial: we
have shown that ET patients with JAK2V617F had more frequent
thrombotic episodes compared with those with wild-type JAK2,
whereas the platelet count at the initial ET diagnosis did not differ
between wild-type ET and JAK2V617F-positive ET.2 On the basis of
this evidence, we retrospectively sought and evaluated thrombo-
tic episodes in ET patients to obtain more insight into the risk
factors of thrombosis in ET patients.
We used the JAK2 mutational status database in 49 patients with
ET in our institute. The JAK2V617F mutation was determined using
by the semiquantitative sequence-specific primer single-molecule
fluorescence detection (SSP-SMPD) assay. As reported previously,
ET patients with JAK2V617F showed a significantly higher incidence
of thrombotic episodes (10/31 versus 1/18: P¼ 0.0308), high
leukocyte count (P¼ 0.0092) and hemoglobin level (P¼ 0.0044)
than those with wild-type JAK2.2 ET patients with thrombosis had
higher hemoglobin (14.571.5 versus 13.371.5 g/dl: P¼ 0.0283)
at initial diagnosis, whereas no significant differences were noted
in leukocyte count (P¼ 0.140), hematocrit level (P¼ 0.0801) or
platelet count (P¼ 0.0877) (Supplementary Information 1). Of the
ET patients with JAK2V617F mutation (n¼ 31), no significant
differences were noted in hematologic parameters regardless of
whether they developed thrombosis or not.
In ET patients followed for at least 1 year, we found 11
patients who suffered thrombosis (Table 1): two patients at
intermediate risk, and nine at high risk, according to the
thrombotic risk.3 Six ET cases were initially diagnosed by
thrombosis, and the remaining five had thrombotic events during
stable phase of the disease. Hematologic parameters at the time
of initial ET diagnosis in these two groups did not significantly
differ, including leukocyte count (P¼ 0.2703), hemoglobin
concentration (P¼ 0.1306), hematocrit level (P¼ 0.4472) or
platelet count (P¼ 0.9662). Except for one patient (JAK2_0050),
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